Diabetes News

Diabetic kidney disease is one of the most frequent complications in both type 1 and type 2 diabetes and the most common cause of chronic kidney disease in the United States.

A cohort of Korean adults who reported brushing their teeth at least three times per day were less likely to develop type 2 diabetes during 10 years of follow-up compared with those who brushed once daily or less, with the presence of periodontal disease and missing teeth further increasing disease risk, according to findings published in Diabetologia.

A large cohort of adults with chronic kidney disease, those with prediabetes were more likely to develop proteinuria or experience a cardiovascular event during 7 years of follow-up compared with those with normoglycemia, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

WASHINGTON — Research presented at ASN Kidney Week suggested a machine learning model that combines blood biomarkers and electronic health record data performed better in predicting rapid kidney function decline in patients with type 2 diabetes than other commonly used models.

LOS ANGELES — In this video exclusive, Robert P. Giugliano, MD, SM, FACC, FAHA, clinical cardiologist at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, presents an overview of recent trials from the Thrombolysis in Myocardial Infarction (TIMI) Study Group that advance the understanding of new therapies for diabetes, cardiovascular disease and beyond.

WASHINGTON — The rate of women hospitalized for acute kidney injury during pregnancy has increased in recent years and is associated with high rates of in-patient mortality, according to research presented at ASN Kidney Week. The risk for pregnancy-related AKI is greatest for women with diabetes, according to the study.

Results from an online survey indicated many Americans are not aware of the association between kidney disease and diabetes. The survey, conducted by The Harris Poll, was commissioned by the National Kidney Foundation.

WASHINGTON — In a secondary analysis of the CREDENCE trial presented here at ASN Kidney Week, researchers focused on subgroups of different GFRs. They determined canagliflozin is safe and effective even for patients with eGFR of 30 mL/min/1.73m2 to less than 45 mL/min/1.73m2.

WASHINGTON — Results from an ancillary study to the Vitamin D and Omega-3 Trial, known as VITAL, demonstrated no difference in eGFR reduction between patients with type 2 diabetes who were assigned to either supplementation or placebo. Data were presented at ASN Kidney Week and simultaneously published in JAMA.

CHICAGO — Healio presents live updates from the late-breaking trials session at the Cardiometabolic Health Congress.